All In Biotech

Investigational drug · Phase 3

ABP 938

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neovascular Age-related Macular Degeneration, nAMD.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "ABP 938"

First trial start

2026

May 27, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ABP 938", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neovascular Age-related Macular Degeneration
  • nAMD

Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "ABP 938" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Neovascular Age-related Macular Degeneration

  • OTX-TKIaxitinib implantPhase 33 trials

    Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)

  • IBI302Phase 32 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema

  • Surabgene LomparvovecABBV-RGX-314Phase 32 trials

    AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration

  • ASKG712AM712, VIS-101Phase 21 trial

    Visara, Inc. · Neovascular Age-related Macular Degeneration

  • RRG001Phase 21 trial

    Shanghai Refreshgene Technology Co., Ltd. · Neovascular Age-related Macular Degeneration

  • SAR402663Phase 21 trial

    Sanofi · Neovascular Age-related Macular Degeneration

  • SYL1801Phase 21 trial

    Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.